Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Xếp hạng trong cổ phiếu #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Giá cổ phiếu
$207.15
Vốn hóa thị trường
$366.28B
Thay đổi (1 ngày)
0.99%
Thay đổi (1 năm)
2.91%
Quốc gia
US
Giao dịch AbbVie Inc. (ABBV)

Danh mục

Doanh thu của AbbVie Inc. (ABBV)
Doanh thu vào Dec 2025 TTM: $61.16B
Theo các báo cáo tài chính gần đây của AbbVie Inc., doanh thu hiện tại của công ty (TTM) là $61.16B. Trong năm 2024, công ty đạt doanh thu $56.33B tăng so với doanh thu năm 2023, là $54.32B. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của AbbVie Inc. từ 2009 đến 2026
Doanh thu vào cuối mỗi năm
Năm Doanh thu Thay đổi
2026 (TTM) $61.16B 0.00%
2025 $61.16B 8.57%
2024 $56.33B 3.71%
2023 $54.32B -6.44%
2022 $58.05B 3.30%
2021 $56.20B 22.69%
2020 $45.80B 37.69%
2019 $33.27B 1.57%
2018 $32.75B 16.08%
2017 $28.22B 10.06%
2016 $25.64B 12.16%
2015 $22.86B 14.52%
2014 $19.96B 6.23%
2013 $18.79B 2.23%
2012 $18.38B 5.37%
2011 $17.44B 11.55%
2010 $15.64B 10.02%
2009 $14.21B 0.00%
Doanh thu của các công ty hoặc đối thủ tương tự
Công ty Doanh thu Chênh lệch doanh thu Quốc gia
$65.18B 6.57%
US
$58.74B -3.96%
GB
$94.19B 54.01%
US
$56.15B -8.19%
CH
$65.01B 6.30%
US